WO2011026351A1 - 一种蓝藻病毒蛋白n 突变体、其修饰衍生物及应用 - Google Patents

一种蓝藻病毒蛋白n 突变体、其修饰衍生物及应用 Download PDF

Info

Publication number
WO2011026351A1
WO2011026351A1 PCT/CN2010/073124 CN2010073124W WO2011026351A1 WO 2011026351 A1 WO2011026351 A1 WO 2011026351A1 CN 2010073124 W CN2010073124 W CN 2010073124W WO 2011026351 A1 WO2011026351 A1 WO 2011026351A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
lcvn
protein
mutant
modified
Prior art date
Application number
PCT/CN2010/073124
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
熊盛
陈伟
钱垂文
王一飞
北里·海雄
Original Assignee
暨南大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 暨南大学 filed Critical 暨南大学
Priority to IN2837DEN2012 priority Critical patent/IN2012DN02837A/en
Priority to JP2012527184A priority patent/JP5592490B2/ja
Publication of WO2011026351A1 publication Critical patent/WO2011026351A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention belongs to the field of biomedicine, and particularly relates to a cyanobacterial virus protein N (CVN) Mutants, their PEG-modified derivatives and their use in pharmaceuticals.
  • CVN cyanobacterial virus protein N
  • Cyanovirin-N (CVN) is an American scientist BOYD A protein that has anti-HIV activity that can be extracted from cyanobacteria. CVN binds specifically and highly affinity to the human immunodeficiency virus HIV-1 capsid protein gp120 It exerts antiviral activity, which makes it immune to virus mutation. It also has the characteristics of wide antiviral spectrum and stable nature, which makes CVN protein a valuable antiviral drug. BOYD M R, GUSTAFSON K R, MCMAHON J B, et al. Discovery of cyanovirin-N, a novel Human immuno- deficiency virus-inactivating protein that binds viral surface Envelope glycoprotein gp120: Potential applications to microbicide development [J].
  • Polyethylene glycol It is a non-toxic, non-immunogenic, water-soluble polymer substance that can be modified by covalent binding. Polyethylene glycol modification is used to solve or alleviate the poor stability of proteins and peptides in the medicinal process. An effective way to solve problems such as short half-life ( IANG Z Y, XU S W, WANG Y Q. Chemistry for pegylation of protein and peptide Molecular [J]. Chinese Journal of Organic Chemistry, 2003, 23 ( 12 ) : 1340-7. Using PEG-maleimide to modify CVN under acidic conditions It has been reported in the literature that Zappe et al. selected a mutant in which 62 glutamine was replaced by a semi-leucine (CVN(Q62C)).
  • mPEG-maleimide mPEG-MAL
  • ZAPPE H SNELL M E
  • BOSSARD M J PEGylation of cyanovirin-N, an entry inhibitor of HIV [J]. Advanced Drug Delivery Reviews, 2008, 60 ( 1 ) : 79-87. ).
  • the specific modification strategy of Zappe et al. is that the molecular weights of the mutants in which 62 and 14 glutamines are replaced by hemi-amino acid are respectively 20KD and 30KD of mPEG-maleimide (mPEG-MAL) were modified under neutral pH and alkaline pH. Results 14
  • the mutant with glutamine replaced by hemi-amino acid (CVN(Q14C)) has a very low modification efficiency, while the mutant with 62 glutamine replaced by hemi-amino acid (CVN(Q62C)) is neutral pH.
  • the modification rate of the CVN mutant with mPEG-MAL molar ratio of 1:3 was higher.
  • CVN Q62C
  • mPEG-maleimide 30KDa mPEG-MAL-30KDa
  • the object of the present invention is firstly to provide a CVN. Mutants, which are easier to express in the host, are easier to purify, and facilitate further modification.
  • Another object of the present invention is to provide the above CVN Modified derivatives of mutants to reduce the cytotoxicity and immunogenicity of the protein itself, making it more suitable for use.
  • a further object of the present invention is to use the above mutants and modified derivatives for the preparation of a medicament for the prevention and/or treatment of AIDS.
  • the present invention provides the following technical solutions:
  • a cyanobacterial virus protein N mutant having an amino acid sequence consisting of sequence A and sequence B, and sequence A is located in sequence B of N End,
  • Sequence A is one of the following:
  • SEQ ID NO: 1 in the sequence listing The amino acid residue sequence is substituted, deleted or added with one or several amino acids, which is hydrophilic and flexible;
  • Sequence B is one of the following:
  • SEQ ID NO: 2 in the sequence listing The amino acid residue sequence is substituted, deleted or added with one or several amino acids, but does not change the first three residues at the N-terminus, and it has specific anti-HIV activity;
  • the present invention also provides a nucleotide sequence encoding a cyanobacterial virus protein N mutant.
  • the above-described coding nucleotide sequence comprises one of the following sequences:
  • the high stringency conditions here refer to low salt high temperature hybridization conditions such as 0.1 ⁇ SSC, 0.1% SDS and 65 °C. Temperature.
  • the above nucleotide sequence can be mainly used for expressing a target protein in a host, and an expression vector, a cell line, a host strain or the like containing the above nucleotide sequence can be obtained by a conventional technical means.
  • the purification process of the protein from the host can also be carried out by a conventional method.
  • the present invention also provides a CVN mutant modified derivative which is the N of the above CVN mutant.
  • the ends are PEG-modified, and the modification sites are generally directed to the ⁇ -amino group of the N-terminal glycine residue.
  • the PEG-modified modifier uses mPEG-ALD (monomethoxy ether PEG-propionaldehyde),
  • the molecular weight of mPEG-ALD is preferably 10KD-20KD.
  • mutants and modified derivatives can be used in the preparation of prophylaxis and / Or the use in the treatment of AIDS drugs, based on the same antiviral mechanism, the mutants and modified derivatives of the present invention can be applied to the preparation of a medicament for preventing and/or treating diseases caused by other viral microorganisms.
  • the present invention has the following beneficial effects:
  • the CVN mutant and the modified derivative thereof provided by the invention are for better realization of the antiviral function of the recombinant CVN in vitro, and the modified L-CVN has enhanced anti-HIV activity (WST method and cell fusion method). Since the LCVN end prepared by the present invention introduces a hydrophilic and flexible polypeptide sequence, N can be performed. Fixed-point amino modification at the end. Our experimental results show that LCVN can not only obtain active modified products after N-terminal amino group modification, but also enhance the antiviral activity of the modified products.
  • Figure 1 is a diagram showing the recombinant plasmid pET3c-6His-SUMO-LCVN.
  • Figure 2 is a recombinant pET3C-6His-SUMO-LCVN plasmid restriction enzyme and PCR analysis, wherein M: DL2000 DNA marker; Lane 1: pET3C-6His-SUMO-LCVN / Nde I+ BamH I; Lane 2: PCR.
  • Figure 3 is an SDS-PAGE electrophoresis analysis of BL21/ pET3c-6His-SUMO-LCVN
  • the expression characteristics of the protein were as follows: from left to right, the lanes were sequentially induced by IPTG without induction, IPTG induction for 20 hours, induced expression of disrupted centrifugal supernatant, and induction of fragmentation and centrifugation.
  • Figure 4 shows the purified target protein LCVN, wherein: from left to right, each lane is Sumo-LCVN fusion protein, Sumo-LCVN fusion protein was digested with Sumo protease, LCVN protein.
  • Figure 5 shows the purity of recombinant LCVN analyzed by RP-HPL.
  • Figure 6 shows the 10K mPEG-ALD modified LCVN at different pH and feed ratios.
  • Tricine-SDS-PAGE electrophoresis map where: from left to right, lane 1 is protein Maker, lanes 2, 3, and 4 are PH3.5, LCVN and 10K mPEG-ALD molar ratio is 1:1, 1:3, 1:5 modified product electrophoresis bands; lanes 5, 6, and 7 are PH4.0, LCVN and 10K mPEG-ALD molar ratio is 1:1, 1:3, 1:5 modified product electrophoresis bands; lanes 8, 9, 10 are PH5.0, LCVN and 10K mPEG-ALD molar ratio is 1:1, 1:3, 1:5 modified product electrophoresis bands; lanes 11, 12, 13 are PH6.0, LCVN The electrophoresis bands of the modified products with the molar ratio of 10K mPEG-ALD were 1:1, 1:3, 1:5; the lanes 14, 15, and 16 were PH7.0,
  • Figure 7 is a comparison of the modification rates of 10K mPEG-ALD modified LCVN under different pH and feed ratio conditions.
  • Figure 8 shows the 20K mPEG-ALD modified LCVN at different pH and feed ratios.
  • Tricine-SDS-PAGE electrophoresis map wherein: from left to right, lane 1 is protein Maker, lanes 2, 3, and 4 are PH3.5, LCVN and 20K, respectively.
  • the mPEG-ALD molar ratio is 1:1, 1:3, 1:5 for the modified product electrophoresis bands; lanes 5, 6, and 7 are PH4.0, LCVN and 20K, respectively.
  • the mPEG-ALD molar ratio is 1:1, 1:3, 1:5 for the modified product electrophoresis bands; lanes 8, 9, and 10 are PH5.0, LCVN and 20K, respectively.
  • the mPEG-ALD molar ratio is 1:1, 1:3, 1:5 for the modified product electrophoresis bands; lanes 11, 12, and 13 are PH6.0, LCVN and 20K mPEG-ALD molar ratio is 1:1, 1:3, 1:5 modified product electrophoresis bands; lanes 14, 15, 16 are PH7.0, LCVN
  • Figure 9 is a comparison of the modification rates of 20K mPEG-ALD modified LCVN under different pH and feed ratio conditions.
  • Figure 10 shows the 10K mPEG-ALD modified LCVN at different times. Tricine-SDS-PAGE electrophoresis map, where lane 1 is protein Maker and lanes 2-8 are 1h, 3h, 5h, 7h, 9h, After 12h and 24h sample electrophoresis results, lane 9 is unmodified LCVN.
  • Figure 11 shows the 20K mPEG-ALD modified LCVN at different times. Tricine-SDS-PAGE electrophoresis map, where lane 1 is protein Maker and lanes 2-8 are 1h, 3h, 5h, 7h, 9h, After 12h and 24h sample electrophoresis results, lane 9 is unmodified LCVN.
  • Figure 12 is 10K mPEG-ALD modified LCVN via SP-Sepharose The purified elution curve was isolated.
  • Figure 13 shows the separation and purification of each component by 10K mPEG-ALD modified LCVN by SP-Sepharose Tricine-SDS-PAGE electropherogram, where lane 1 is protein Maker, lane 2-5 is a mixture of modification reactions, loading peaks, containing 80 mM NaCl The elution peak of buffer A; the elution peak of buffer A containing 400 mM NaCl.
  • Figure 14 is 20K mPEG-ALD modified LCVN via SP-Sepharose The purified elution curve was isolated.
  • Figure 15 is a 20K mPEG-ALD modified LCVN separated and purified by SP-Sepharose Tricine-SDS-PAGE electrophoresis map, wherein: lane 1 is protein Maker, lanes 2-5 are mixtures of modification reactions, loading breakthrough peaks, containing 70 mM NaCl The elution peak of buffer A; the elution peak of buffer A containing 400 mM NaCl.
  • Figure 16 shows the cell viability (%) of MT-4 after treatment with different concentrations of LCVN and its modified products.
  • Figure 17 shows the inhibition rate (%) of CVN and LCVN on HIV-1/IIIB proliferation.
  • Figure 18 is an anti-human immunodeficiency virus activity of LCVN and its PEG-modified product, wherein (1) MOLT-4 cells, (2) MOLT-4/IIIB cells, and (3) cells after co-culture, observed under phase contrast microscopy, (4) Pseudo-treated co-cultured cells, (5-8) CVN/LCVN/10kPEG-LCVN/20kPEG-LCVN at a concentration of 113 nM Co-cultured cells after treatment, indicated by black arrows, are fused large cells.
  • Figure 19 shows the CPE of LCVN and its PEG modified product against HSV-1 activity. Observation results. among them:
  • A normal control
  • B virus control
  • C positive drug ACV control (1 ⁇ g/ml)
  • D L-CVN sample ( 1.562 ⁇ g/ml)
  • E SUMO-L-CVN sample ( 3.125 ⁇ g/ml)
  • F mPEG-ALD-10kDa-L-CVN ( 3.125 ⁇ g/ml )
  • G mPEG-ALD-20kDa-L-CVN ( 3.125 ⁇ g/ml ).
  • the main materials involved in the examples of the present invention are as follows: Host strain Escherichia coli BL21 (DE3) (purchased from Novagen), plasmid pET3c (purchased from Novagen), pET3c-SUMO-CVN is preserved by the laboratory (the construction method has been patented)
  • the preparation method and application of recombinant cyanobacterial antiviral protein, application number: 200810198926.0” the construction of the plasmid can also adopt the well-known genetic engineering method, the basic idea is to first obtain the SUMO-CVN fusion sequence by PCR, and then connect to the pET3c vector.
  • Plasmid pET3c-SUMO-CVN Plasmid pET3c-SUMO-CVN); SUMO protease (purchased from Haiji Biotechnology Co., Ltd.); Taq enzyme, T4 DNA ligase, DNA molecular weight standard, various restriction enzymes purchased from Dalian Bao Biotech Co., Ltd.; Standards (purchased from Juyan Biotechnology Co., Ltd.), primers purchased from Shanghai Shenggong Biotech Co., Ltd.; Ni 2 + Sepharose Fast Flow, SP Sepharose Fast Flow from GE Healthcare; MTT and WST from SIGMA, USA; Herpes simplex Virus type 1 ( HSV-1 ) F strain from Wuhan University Virus Research Institute ( CGMCC No.0396 ); Vero cells CCL-81TM), MOLT-4 cells (CRL-1582TM), MT-4 cells (CRL-1942TM), HIV-I/IIIB virus (CRL-1973TM), etc. from the American Type Culture Collection (ATCC) mPEG-ALD (10
  • NTA-0 buffer 20mmol/L Tris-HCl , pH 8.0 , 0.15mol /L NaCl ,
  • NTA-20 buffer 20mmol/L Tris-HCl , pH 8.0 , 0.15mol /L NaCl , 20mmol/L imidazole
  • NTA-250 buffer (20mmol/L Tris-HCl, pH 8.0, 0.15mol / L NaCl, 250mmol/L imidazole
  • digestion buffer (20mmol/L Tris-HCl, pH 8.0, 0.15mol/L NaCl
  • bufferA 20 mmol/L NaAc-Ac, pH 4.0).
  • the construction of the SUMO-L-CVN gene was synthesized in two steps.
  • the L-CVN gene was synthesized by two PCRs, the first time.
  • PCR uses pET3c-SUMO-CVN plasmid as template and F1-CVN and R-CVN as upstream and downstream primers.
  • the reaction system is 1 ng for the template and 1 ⁇ M for each of the upstream and downstream primers.
  • 20 ⁇ l Taq PCR MasterMix add water to 40 ⁇ l, the reaction mixture is denatured at 94 °C for 1min, annealed to 55 °C for 1 min, 72 °C Extend 1 min for 29 cycles.
  • the reaction product was subjected to 1% agarose gel electrophoresis, and the target fragment was recovered by gel as a template for the next round of PCR.
  • Second PCR above one round of PCR The product is a template, F2-CVN and R-CVN are upstream and downstream primer pairs (where the F2-CVN primer contains a flexible polypeptide encoding 15 amino acid residues), and the full-length sequence of L-CVN is synthesized.
  • the SUMO full-length sequence was synthesized from pET3c-SUMO-CVN by PCR.
  • the full-length sequences of plasmid pET3C and 6His-SUMO-LCVN were digested with Nde I and BamH I respectively, and the digested product was subjected to 1% agarose gel electrophoresis, and the digested product was recovered, T 4 DNA ligase, and the ligation product was transformed into the large intestine.
  • Bacterial JM109 competent cells were plated on LB plates containing ampicillin and cultured overnight at 37 °C. Plasmids were extracted, amplified by PCR and identified by double digestion with Nde I and BamH I. The positive plasmids were sent to Yingjun for sequencing.
  • the cells were collected by centrifugation at 10 min, frozen and thawed, and then the cells were resuspended in NTA-10 buffer at a ratio of 1:10, sonicated (working time 5 s, intermittent time) 5s, 99 times, repeated 3 times), the supernatant was collected by centrifugation at 4 ° C, 25000 ⁇ g, 30 min.
  • the supernatant was loaded with a 20 ml Ni-NTA affinity column at a flow rate of 0.6 ml/min, NTA-0.
  • the buffer was washed back to the baseline at a flow rate of 1 ml/min, NTA-20 buffer washed protein, and NTA-250 buffer eluted the target protein.
  • Purified target protein 6His-SUMO-LCVN was subjected to deamidation by Sephadex G-25 molecular sieve and then subjected to SUMO protease digestion to remove the SUMO fusion protein.
  • 6His-SUMO-LCVN Adjust the concentration to 1mg/ml and add 1 U SUMO protease /mg Fusion protein, digested at 30 ° C for 1 h. Because the 6His-SUMO tag and SUMO protease both contain a 6 ⁇ His tag, the digested sample is loaded again. Ni-NTA The affinity column was purified to remove the 6His-tagged SUMO, un-cut 6His-SUMO-LCVN and SUMO protease to obtain the non-fused target protein LCVN. The G-25 molecular sieve column is desalted and freeze-dried to obtain LCVN products for subsequent physical and chemical properties determination, activity determination or PEG modification.
  • Figure 3 is the engineering strain BL21[ pET3c-6His-SUMO-LCVN] by IPTG
  • the protein expression profile after induction showed that after induction, a significantly thickened protein band (lane 3) appeared at a molecular weight of 28 kD, and 6His-SUMO-LCVN The theoretical molecular weight is consistent.
  • the target protein is located in the supernatant of the broken cell, which accounts for 40% of the soluble protein of the bacteria (lane 2).
  • Figure 4 is an SDS-PAGE analysis of LCVN Purification process, where * is shown as 6His-SUMO-LCVN fusion protein, and ** is shown as LCVN protein.
  • FIG. 5 is a reverse high performance liquid chromatography of LCVN products ( RP-HPLC) Purity analysis results, the plant type is a C-18 reverse column with a detector wavelength of 280 nm, mobile phase A: ultrapure water containing 0.1% trifluoroacetic acid (TFA), mobile phase B : Ethyl cyanide, gradient elution with 40% -60% B, and elution peak of LCVN with retention time between 4-6 min.
  • TFA trifluoroacetic acid
  • the engineered strain BL21[pET3c-6His-SUMO-LCVN] was selected and cultured and induced to express in a test tube, and a high expression strain was selected for pilot fermentation.
  • Primary and secondary seeds were cultured in conical flasks, secondary seeds were incubated to appropriate concentrations, and inoculated into 15 L of fermentation medium at 10% inoculum.
  • the temperature is automatically controlled at 37 °C, and the speed and ventilation are adjusted in time to maintain a proper dissolved oxygen level.
  • the pH is adjusted to 7.0 to 7.2 with NaOH and HCl.
  • the cell density (OD 600 ) was about 12
  • the temperature was lowered to 20 °C
  • IPTG was added to a final concentration of 0.5 mM to induce expression for 20 h.
  • 100 ml/min, 9000 g the cells were collected by continuous flow centrifugation, and about 550 g of wet cells were harvested in a 15 L fermentation medium, and the collected cells were stored in a refrigerator
  • the cell pellet was suspended in NTA-0 buffer at a ratio of 1:10, sonicated (working time 5s, intermittent time) 5s, 99 times, repeated 3 times), the supernatant was collected by centrifugation at 4 ° C, 25000 ⁇ g, 30 min.
  • the loading of Ni-NTA packing with a volume of 20 ml is 250ml supernatant, flow rate 1ml/min, NTA-0 buffer wash back to baseline; flow rate 1ml/min, NTA-20 buffer wash protein, NTA-250 Buffer elutes the protein of interest.
  • the purified target protein 6His-SUMO-LCVN is subjected to SUMO protease digestion by removing the imidazole from Sephadex G-25 molecular sieve. SUMO fusion protein.
  • 6His-SUMO-LCVN Adjust the concentration to 1mg/ml and add 1 U SUMO protease /mg Fusion protein, digested at 30 ° C for 1 h. Because the 6His-SUMO tag and SUMO protease both contain a 6 ⁇ His tag, the digested sample is loaded again. Ni-NTA The affinity column was purified to remove the 6His-tagged SUMO, un-cut 6His-SUMO-LCVN and SUMO protease to obtain the non-fused target protein LCVN. Replace the buffer with G-25 molecular sieve column and concentrate the LCVN protein with a 3KD ultrafiltration tube for subsequent physical and chemical determination, activity determination or PEG modification.
  • PEG modification of pharmaceutical proteins is an effective method to improve various drug properties such as pharmacokinetic properties, stability and immunogenicity.
  • Protein available PEG-modified sites include side chain amino groups, N-terminal amino groups, side chain carboxyl groups, C A terminal carboxyl group, a side chain thiol group, and the like.
  • Existing carboxyl modification techniques are prone to non-specific cross-linking reactions, so amino modification is more common and technological development is more mature.
  • Zappe et al.'s findings indicate that wild-type CVN The modification of the side chain amino or N-terminal amino group will destroy the activity of the protein. Therefore, the author first performs site-directed mutagenesis of CVN to obtain the Q62C mutant, and then introduced the Cys introduced at position 62.
  • the side chain thiol modification was carried out to obtain an active protein. Due to the formation of 4 Cys residues in the native CVN 2 For disulfide bonds, and in solution, the disulfide bond of the protein is in a dynamic isomeric and equilibrium state. Therefore, after introducing the Q62C mutation, it is difficult to prevent the introduced Cys from interfering with the correct matching of the disulfide bond, or non-62 position. Cys modification, the authors' final experimental results also showed that the activity of CVN Q62C mutant and its modified products were lower than wild-type CVN.
  • LCVN end prepared by the present invention introduces a hydrophilic and flexible 15-peptide sequence, an attempt can be made to N. Fixed-point amino modification at the end. Our experimental results show that LCVN can not only obtain active modified products after N-terminal amino group modification, but also enhance the antiviral activity of the modified products.
  • the present invention selects mPEG-ALD (10K) and mPEG-ALD (20K) was used as a modifier to screen the optimal PEG modification conditions for LCVN from three aspects: substrate ratio, modifier ratio, modification pH and modification reaction time.
  • mPEG-ALD (10K) and mPEG-ALD (20K) modification at the optimum pH and feed ratio determined LCVN was sampled at 1h, 3h, 5h, 7h, 9h, 12h and 24h, and the optimal reaction time was identified by Tricine-SDS-PAGE electrophoresis.
  • the results of SDS-PAGE analysis indicated that the reaction time was modified by mPEG-ALD (10K) and mPEG-ALD (20K). The reaction did not have a significant effect, considering the time cost, preferably the optimal modification reaction time was 2 h at room temperature (Fig. 10 and Fig. 11).
  • the reaction mixture mainly contains unmodified LCVN and the remaining PEG.
  • PEG multi-modified LCVN PEG single-modified LCVN.
  • AKTA prime plus separation and purification system SP sepharose column
  • the single modified mPEG-ALD-LCVN was isolated and purified, and the mobile phase was 20 mM Na-Ac buffer (buffer A), and 5 column volumes were used before loading.
  • bufferA equilibrate the column, collect the breakthrough peak after loading, and then elute with bufferA containing different concentrations of NaCl to collect each elution peak.
  • the flow rate is 1ml/min and the detection wavelength is 280nm.
  • the collected samples were detected by SDS-PAGE gel electrophoresis.
  • mPEG-ALD (10K) modified LCVN mixture after purification by SP sepharose cation chromatography, the modifier mPEG-ALD and multi-modification products were not penetrated by SP sepharose, and the buffer A elution product containing 80 mM NaCl was single.
  • Modified mPEG-ALD (10K) -LCVN; buffer A eluting product containing 400 mM NaCl is unmodified LCVN.
  • Figure 12 shows the elution curve of mPEG-ALD (10K) -LCVN separation and purification. Peak 1 is the modifier and multi-modification product, peak 2 is the single modification product, and peak 3 is the unmodified substrate.
  • Figure 13 shows the elution components by SDS-PAGE.
  • Lane M is the protein molecular weight standard
  • Lane A is the sample, showing unmodified substrate, single modified product and multiple modified products
  • Lane 1 is the breakthrough peak
  • Lane 2 It is a single modified product, that is, the target protein mPEG-ALD (10K) -LCVN
  • Lane 3 is an unmodified product.
  • mPEG-ALD (20K) modified LCVN mixture after purification by SP sepharose cation chromatography, the modifier mPEG-ALD and multi-modification products were also present in the loading peak, and the buffer A eluting product containing 70 mM NaCl was single.
  • Figure 14 shows the elution curve of mPEG-ALD (20K) -LCVN separation and purification. Peak 1 is the modifier and multi-modification product, peak 2 is the single modification product, and peak 3 is the unmodified substrate.
  • Figure 15 shows the elution components by SDS-PAGE. Lane M is the protein molecular weight standard; Lane A is the sample, showing unmodified substrate, single modified product and multiple modified products; Lane 1 is the breakthrough peak; Lane 2 Is a single modified product, that is, the target protein mPEG-ALD (10K) -LCVN; Lane 3 is a 400 mM NaCl elution component, showing unmodified products, but also
  • CVN, LCVN and PEG modified products were serially diluted in RPMI-1640 medium and added to 96-well cell culture plates at 50 ⁇ l per well.
  • CVN and LCVN were diluted from 10 ⁇ g/ml to 0.04 ⁇ g/ml.
  • PEG-modified LCVN The dilution range is from 50 ⁇ g/ml to 0.19 ⁇ g/ml.
  • the MT-4 cells were adjusted to a concentration of 1 ⁇ 10 5 /ml, 100 ⁇ l per well, mixed, and cultured in a 37 ° C, 5% CO 2 cell incubator, with a cell control and a positive drug control (63 nM azidothymidine, AZT), 3 replicate wells were determined in parallel for each sample.
  • WST-1 water-soluble tetrazolium, 5 mmol/L
  • the absorbance (A) was read on the plate reader, and the wavelength was calculated at 450/650 nm.
  • Cell viability (%) drug treatment group A value / cell control group A Value ⁇ 100%.
  • Figure 16 shows cell viability after treatment with four different proteins, CVN, LCVN and their modified products.
  • N.C. refers to an untreated cell control with a cell control density of 100%.
  • AZT is a positive control drug, 63 nM azidothymidine. The calculated 50% toxic concentration is shown in Table 2. Shown.
  • CVN, LCVN and PEG modified products were serially diluted in RPMI-1640 medium and added to 96-well cell culture plates at 50 ⁇ l per well. Adjust the concentration of MT-4 cells to 1 ⁇ 10 5 /ml, 100 ⁇ l per well, mix, and then add 50 ⁇ l of HIV-1/IIIB virus suspension with a titer of 100 TCID50. The cells were cultured in a 37 ° C, 5% CO 2 cell incubator, and a cell control, virus control, and positive drug control (azidothymidine, AZT) were set. Three replicate wells were determined in parallel for each sample.
  • WST-1 water-soluble tetrazolium, 5 mmol/L
  • Cell viability (%) drug treatment group A value / cell control group A Value ⁇ 100%.
  • Virus inhibition rate (%) (drug treatment group A 450/650 - virus control group A 450/650 ) / (cell control group A 450/650 - virus control group A 450/650 ) ⁇ 100%
  • MOLT-4 cells and MOLT-4/IIIB cells grown to log phase were adjusted to a density of 1 ⁇ 10 6 /ml, and 250 ⁇ l of each cell suspension was mixed in equal volumes and added to a 24-well cell culture plate (the total number of cells was 5 ⁇ 10 5 /500 ⁇ l/well); CVN, LCVN and its PEG-modified products were serially diluted 4 times in RPMI-1640 medium containing fetal bovine serum and antibiotics, and 3 concentrations were selected for each test drug (452 nM, 113 nM). , 28 nM ), an equal volume was added to the cell suspension, and various control groups were set at the same time.
  • MOLT-4/IIIB cells can continuously produce HIV-I/IIIB virus particles and form large multinucleated cells (synaptosomes) by fusion with normal MOLT-4 cells to infect normal host cells, at the time of cell counting, fusion The cells cannot enter the counting pool.
  • the number of cells forming the syncytia can be estimated, and the number of cells in the co-culture group is compared and not co-cultured.
  • the number of MOLT-4 cells in the group calculate the fusion index (FI, fusion index):
  • FI 1 - (Number of cells in co-cultured cell wells ⁇ Number of cells in control wells containing only MOLT-4 cells)
  • FIR (%) [1-(FI T /FI C )] ⁇ 100 , where FI T is the fusion index of the administered sample, and FI C is the fusion index of the unadministered co-cultured cells.
  • Figure 18 shows the (1) MOLT-4 cells after incubation for 24 h under a phase contrast microscope, (2) MOLT-4/IIIB cells, (3) co-cultured cells, (4) sham-treated co-cultured cells, (5-8) at a concentration of 113 nM CVN/LCVN/10kPEG-LCVN/20kPEG-LCVN After the treatment, the co-cultured cells showed large cells fused as indicated by black arrows. No fused cells were observed in the unco-cultured group, and typical fused cells appeared in the co-culture group, while the conjugated cells were not observed in the drug-administered group.
  • Figure 18 (b) is CNV, LCVN, 10kPEG-LCVN, 20kPEG-LCVN
  • the fusion inhibition activity, all experiments are at least 3 statistical results after independent experiments. It can be seen that the fusion inhibitory activity of LCVN on HIV-1/IIIB is significantly higher than that of CVN in any dose group.
  • the PEG-modified product of LCVN gradually increased in activity with increasing molecular weight, but in the low-dose group, PEG The activity of the modified product gradually decreases as the molecular weight increases.
  • Herpes simplex virus type 1 is a DNA that causes widespread infection in the human population. Virus, human being is the only host, and about 90% of healthy adults are infected with HSV-1. HSV-I can cause various diseases such as cold sore, herpetic keratoconjunctivitis and neonatal encephalitis due to HSV-I It can be latent infection in the ganglion, so the symptoms are easy to relapse.
  • HSV-I Herpes simplex virus type 1
  • the toxicity of recombinant LCVN and its modified products and wild-type CVN to Vero cells was determined by MTT assay; CPE The method observes the activity of the drug on the cells.
  • Figure 19 It is the morphology of the cells under a phase contrast microscope after a typical experiment, showing the cytopathic effect of the virus on the cells and the protective effect of the drugs on the cells.
  • the results showed that LCVN and its modified products have good resistance.
  • HSV-1 activity, LCVN and its PEG modified products showed positive control drug ACV under the conditions of close mass concentration and lower molar concentration. Basically close to antiviral activity.
  • the toxicity test results showed that the toxicity of LCVN modified by PEG to Vero cells was also significantly reduced.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PCT/CN2010/073124 2009-09-04 2010-05-24 一种蓝藻病毒蛋白n 突变体、其修饰衍生物及应用 WO2011026351A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN2837DEN2012 IN2012DN02837A (enrdf_load_stackoverflow) 2009-09-04 2010-05-24
JP2012527184A JP5592490B2 (ja) 2009-09-04 2010-05-24 シアノビリン−ｎ変異体、その修飾誘導体及びその応用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910192063.0 2009-09-04
CN2009101920630A CN101638435B (zh) 2009-09-04 2009-09-04 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用

Publications (1)

Publication Number Publication Date
WO2011026351A1 true WO2011026351A1 (zh) 2011-03-10

Family

ID=41613629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/073124 WO2011026351A1 (zh) 2009-09-04 2010-05-24 一种蓝藻病毒蛋白n 突变体、其修饰衍生物及应用

Country Status (4)

Country Link
JP (1) JP5592490B2 (enrdf_load_stackoverflow)
CN (1) CN101638435B (enrdf_load_stackoverflow)
IN (1) IN2012DN02837A (enrdf_load_stackoverflow)
WO (1) WO2011026351A1 (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110903363A (zh) * 2019-11-26 2020-03-24 中国药科大学 一种蓝藻抗病毒蛋白n的制备方法及应用
WO2022072469A1 (en) * 2020-09-29 2022-04-07 Drexel University Compositions for inhibiting viral entry and methods using same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101638435B (zh) * 2009-09-04 2011-11-16 暨南大学 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用
MX370715B (es) * 2013-02-05 2019-12-20 Agricultural Tech Res Inst Vacuna de subunidades anti-mycoplasma spp.
CN111494604B (zh) * 2020-05-11 2022-05-06 中国药科大学 蓝藻抗病毒蛋白n在制备抗炎药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7267941B2 (en) * 2002-12-19 2007-09-11 The Government of the United States of America as represented by The Secretary of The Department of Health and Human Services, The National Institutes of Health Cyanovirin variant-polymer conjugates
CN101638435A (zh) * 2009-09-04 2010-02-03 暨南大学 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用
CN101705241A (zh) * 2008-09-28 2010-05-12 暨南大学 重组蓝藻抗病毒蛋白的制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843882A (en) * 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
EP1488804A4 (en) * 2002-03-22 2006-10-25 Bipha Corp IMMUNOGLOBULIN / HYDROPHILIC PEPTIDE COMPLEXES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7267941B2 (en) * 2002-12-19 2007-09-11 The Government of the United States of America as represented by The Secretary of The Department of Health and Human Services, The National Institutes of Health Cyanovirin variant-polymer conjugates
CN101705241A (zh) * 2008-09-28 2010-05-12 暨南大学 重组蓝藻抗病毒蛋白的制备方法及应用
CN101638435A (zh) * 2009-09-04 2010-02-03 暨南大学 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN QUAN ET AL: "Progress in SUMO modification research", CHINESE BULLETIN OF LIFE SCIENCES, vol. 16, no. 1, 1 March 2004 (2004-03-01), pages 1 - 6 *
H.ZAPPE ET AL: "PEGylation of cyanovirin-N, an entry inhibitor of HIV", ADVANCED DRUG DELIVERY REVIEWS, vol. 60, 31 December 2008 (2008-12-31), pages 79 - 87, XP022370574, DOI: doi:10.1016/j.addr.2007.05.016 *
LI QI-YUAN ET AL: "Advanced in research of cyanovirin N, a HIV-inactivating protein", CHIN J NEW DRUGS CLIN REM, vol. 22, no. 6, 30 June 2003 (2003-06-30), pages 371 - 375 *
WU JIE ET AL: "PEG modification of protein drug", PROGRESS IN PHARMACEUTICAL SCIENCES, vol. 26, no. 2, 31 December 2002 (2002-12-31), pages 146 - 151 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110903363A (zh) * 2019-11-26 2020-03-24 中国药科大学 一种蓝藻抗病毒蛋白n的制备方法及应用
WO2022072469A1 (en) * 2020-09-29 2022-04-07 Drexel University Compositions for inhibiting viral entry and methods using same

Also Published As

Publication number Publication date
JP2013503609A (ja) 2013-02-04
JP5592490B2 (ja) 2014-09-17
CN101638435A (zh) 2010-02-03
CN101638435B (zh) 2011-11-16
IN2012DN02837A (enrdf_load_stackoverflow) 2015-07-24

Similar Documents

Publication Publication Date Title
AU2022268401B2 (en) Conjugates of an IL-2 moiety and a polymer
WO2011026351A1 (zh) 一种蓝藻病毒蛋白n 突变体、其修饰衍生物及应用
CN104302772B (zh) 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
EP2007804B1 (en) Glp-1 compounds
CN115920077A (zh) 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物
NO317129B1 (no) Interlaukin 1<beta> protease og interlaukin 1<beta> proteaseinhibitorer
WO2020218829A1 (ko) 플라젤린 융합 단백질 및 이의 용도
JP2008515437A (ja) 血管活性腸管ポリペプチド医薬品
WO2004048401A1 (ja) ペプチド及びこれを含む医薬組成物
WO2024204896A1 (en) Genetically modified cells into which a nucleic acid encoding a stefin a protein variants specifically binding to tnfr2 or a fusion protein comprising the same has been introduced, and uses thereof
EP1131352A2 (en) Rantes-derived peptides with anti-hiv activity
WO2011049350A2 (ko) 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
EP1357929A2 (en) Modulation of immune response and methods based thereon
EP3057982A1 (en) Fused proteins of interferon alpha 5 with another cytokine and a process for producing thereof
CHEN et al. Overexpression of soluble human thymosin alpha 1 in Escherichia coli
WO2011010337A9 (en) Vaccines based on genetic chimera of viral and/or tumoral antigens and vegetable proteins
KR20220054612A (ko) 융합 단백질 및 이의 용도
Won et al. Simple purification of Escherichia coli-derived recombinant human interleukin-2 expressed with N-terminus fusion of glucagon
HK40053166A (en) Conjugates of an il-2 moiety and a polymer
曹俊霞 Cloning and expression of recombinant human thymosin in yeast Pichia pastoris

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10813273

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012527184

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2837/DELNP/2012

Country of ref document: IN

122 Ep: pct application non-entry in european phase

Ref document number: 10813273

Country of ref document: EP

Kind code of ref document: A1